Pyxis Oncology (PYXS) Revenue (2024 - 2025)

Pyxis Oncology's (PYXS) quarterly Revenue came in at $11.0 million in Q4 2025, up 291.42% on a QoQ basis from $2.8 million in Q2 2025.

Pyxis Oncology (PYXS) Revenue (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has 2 years of Revenue data on file, last reported at $11.0 million in Q4 2025.

On a quarterly basis, Revenue changed N/A year-over-year to $11.0 million in Q4 2025; TTM through Dec 2025 was $13.9 million, a 14.17% decrease from a year earlier, with the FY2025 full-year figure at $13.9 million, down 14.17% from the prior year.
Revenue for Q4 2025 stood at $11.0 million, up from $2.8 million in the prior quarter.
Over the last five years, Revenue for PYXS reached as high as $16.1 million in Q1 2024 and fell as low as $2.8 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	1.51 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.56 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Pyxis Oncology	166.54 Mn	99.69 Mn	8.65 Mn	11.04 Mn

Download Data